Glutamate treatment and p25 transfection increase Cdk5 mediated tau phosphorylation in SH-SY5Y cells
- 23 June 2006
- journal article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 345 (1), 324-331
- https://doi.org/10.1016/j.bbrc.2006.04.032
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- A survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brainsFEBS Letters, 2002
- Regulation of NMDA receptors by cyclin-dependent kinase-5Proceedings of the National Academy of Sciences of the United States of America, 2001
- Regulation of N-cadherin-mediated adhesion by the p35–Cdk5 kinaseCurrent Biology, 2000
- Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegenerationNature, 1999
- The p35/Cdk5 kinase is a neuron-specific Rac effector that inhibits Pak1 activityNature, 1998
- Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death.Proceedings of the National Academy of Sciences of the United States of America, 1996
- The cdk5/p35 kinase is essential for neurite outgrowth during neuronal differentiation.Genes & Development, 1996
- p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5Nature, 1994
- Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology.Proceedings of the National Academy of Sciences of the United States of America, 1986
- Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease.Proceedings of the National Academy of Sciences of the United States of America, 1986